{"id":67048,"date":"2026-05-14T15:19:38","date_gmt":"2026-05-14T09:49:38","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=67048"},"modified":"2026-05-14T15:19:40","modified_gmt":"2026-05-14T09:49:40","slug":"cipla-limited-jumps-8-despite-q4-profit-decline-what-is-driving-investor-optimism","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/cipla-limited-jumps-8-despite-q4-profit-decline-what-is-driving-investor-optimism\/","title":{"rendered":"Cipla Limited Jumps 8% Despite Q4 Profit Decline: What Is Driving Investor Optimism?"},"content":{"rendered":"
<\/div>\n

Summary<\/strong><\/h2>\n\n\n\n

Shares of Cipla Limited surged nearly 8% even though the company reported a decline in its Q4 profit. The sharp rise surprised many investors because markets usually react negatively to falling profits. However, the rally was driven by stronger-than-expected operational performance, stable revenue growth, improving margins in key businesses, positive management commentary, and optimism around future growth opportunities in domestic pharma and exports. Investors also appeared encouraged by the company\u2019s strategic focus on respiratory therapies, complex generics, and steady expansion in international markets. The stock market\u2019s reaction highlighted an important reality: markets often focus more on future earnings visibility and business quality than just quarterly profit numbers.<\/p>\n\n\n\n

Why Cipla\u2019s Q4 Results Matter to Investors<\/strong><\/h2>\n\n\n\n

The Indian pharmaceutical sector has always been closely watched by investors because it combines defensive stability with long term growth potential. Among the leading pharma companies in India, Cipla Limited holds a special position due to its strong presence in respiratory medicines, chronic therapies, and global generics.<\/p>\n\n\n\n

So when Cipla announced a decline in quarterly profit but still saw its stock jump sharply, the market reaction naturally caught attention.<\/p>\n\n\n\n

For retail investors, this raises an important question: Why would a stock rise despite weaker profits?<\/p>\n\n\n\n

The answer lies in how markets interpret earnings beyond headline numbers. Investors today are not just looking at quarterly profits. They are evaluating:<\/p>\n\n\n\n

    \n
  • Future growth visibility<\/li>\n\n\n\n
  • Operational strength<\/li>\n\n\n\n
  • Margin stability<\/li>\n\n\n\n
  • Product pipeline<\/li>\n\n\n\n
  • Export opportunities<\/li>\n\n\n\n
  • Management confidence<\/li>\n<\/ul>\n\n\n\n

    Cipla\u2019s latest earnings reinforced confidence in several of these areas, which helped the stock rally despite the profit decline.<\/p>\n\n\n\n

    Understanding Cipla\u2019s Business and Market Position<\/strong><\/h2>\n\n\n\n

    Before analysing the market reaction, it is important to understand what makes Cipla Limited one of India\u2019s major pharmaceutical companies.<\/p>\n\n\n\n

    Founded in 1935, Cipla has built a strong presence across:<\/p>\n\n\n\n

      \n
    • Respiratory medicines<\/li>\n\n\n\n
    • Anti infectives<\/li>\n\n\n\n
    • Cardiac treatments<\/li>\n\n\n\n
    • Urology<\/li>\n\n\n\n
    • HIV therapies<\/li>\n\n\n\n
    • Consumer healthcare<\/li>\n\n\n\n
    • Generic medicines<\/li>\n<\/ul>\n\n\n\n

      The company operates in India as well as multiple global markets including:<\/p>\n\n\n\n

        \n
      • United States<\/li>\n\n\n\n
      • South Africa<\/li>\n\n\n\n
      • Europe<\/li>\n\n\n\n
      • Emerging markets<\/li>\n<\/ul>\n\n\n\n

        Over the years, Cipla has gained recognition for making affordable medicines accessible, particularly in respiratory and life saving therapies.<\/p>\n\n\n\n

        Its diversified business model helps reduce dependence on a single geography or therapy segment, which investors generally view positively.<\/p>\n\n\n\n

        Why Did Cipla Shares Jump Despite Profit Decline?<\/strong><\/h2>\n\n\n\n

        The key reason behind the rally was that investors looked beyond the headline profit decline and focused on the overall quality of the earnings.<\/p>\n\n\n\n

        Here are the major factors that likely supported the stock:<\/p>\n\n\n\n

        Strong Revenue Performance<\/strong><\/h3>\n\n\n\n

        While profit may have declined, revenue growth remained healthy in several business segments.<\/p>\n\n\n\n

        The market generally rewards companies that continue showing stable demand and revenue expansion, especially during uncertain economic conditions.<\/p>\n\n\n\n

        Cipla\u2019s domestic formulations business reportedly remained resilient, supported by strong demand in chronic therapies and respiratory products.<\/p>\n\n\n\n

        Positive Management Commentary<\/strong><\/h3>\n\n\n\n

        Investor confidence often depends heavily on management guidance.<\/p>\n\n\n\n

        Markets appeared encouraged by the company\u2019s outlook on:<\/p>\n\n\n\n

          \n
        • Future growth visibility<\/li>\n\n\n\n
        • Product pipeline<\/li>\n\n\n\n
        • Export opportunities<\/li>\n\n\n\n
        • Margin stability<\/li>\n\n\n\n
        • Demand trends<\/li>\n<\/ul>\n\n\n\n

          When management commentary remains optimistic, investors tend to look past temporary quarterly fluctuations.<\/p>\n\n\n\n

          Operational Strength and Margin Focus<\/strong><\/h3>\n\n\n\n

          Even when net profit declines, operational indicators such as EBITDA margins, cost control, and product mix improvements can reassure investors.<\/p>\n\n\n\n

          Cipla has been focusing on improving efficiency and strengthening high margin businesses.<\/p>\n\n\n\n

          This likely supported market sentiment.<\/p>\n\n\n\n

          Stability in Domestic Pharma Business<\/strong><\/h3>\n\n\n\n

          India\u2019s domestic pharmaceutical market continues to grow steadily due to:<\/p>\n\n\n\n

            \n
          • Rising healthcare awareness<\/li>\n\n\n\n
          • Increasing chronic diseases<\/li>\n\n\n\n
          • Higher healthcare spending<\/li>\n\n\n\n
          • Improved access to medicines<\/li>\n<\/ul>\n\n\n\n

            Cipla\u2019s strong domestic presence remains one of its biggest strengths.<\/p>\n\n\n\n

            Investors may have viewed this as a long term positive despite short term profit pressure.<\/p>\n\n\n\n

            Export Market Optimism<\/strong><\/h3>\n\n\n\n

            The pharmaceutical export business remains an important growth driver for Indian pharma companies.<\/p>\n\n\n\n

            Investors appear optimistic about Cipla\u2019s opportunities in:<\/p>\n\n\n\n

              \n
            • US generics market<\/li>\n\n\n\n
            • Respiratory products<\/li>\n\n\n\n
            • Complex generics<\/li>\n\n\n\n
            • Emerging markets<\/li>\n<\/ul>\n\n\n\n

              Growth visibility in international markets often influences valuations significantly.<\/p>\n\n\n\n

              What Caused the Decline in Q4 Profit?<\/strong><\/h2>\n\n\n\n

              Although the market reacted positively, the decline in profit still deserves attention.<\/p>\n\n\n\n

              Several factors may have contributed to weaker quarterly profitability.<\/p>\n\n\n\n

              Pricing Pressure in Export Markets<\/strong><\/h3>\n\n\n\n

              Indian pharma companies often face pricing pressure in global generic markets, especially in the US.<\/p>\n\n\n\n

              Competition can impact profitability even if sales volumes remain stable.<\/p>\n\n\n\n

              Higher Operational Costs<\/strong><\/h3>\n\n\n\n

              Companies across sectors are dealing with rising:<\/p>\n\n\n\n

                \n
              • Input costs<\/li>\n\n\n\n
              • Employee expenses<\/li>\n\n\n\n
              • Compliance costs<\/li>\n\n\n\n
              • Logistics expenses<\/li>\n<\/ul>\n\n\n\n

                These pressures can temporarily affect profit margins.<\/p>\n\n\n\n

                Base Effect<\/strong><\/h3>\n\n\n\n

                Sometimes profit declines happen because the previous year\u2019s quarter had unusually high earnings.<\/p>\n\n\n\n

                This creates a difficult comparison base.<\/p>\n\n\n\n

                Product Mix Changes<\/strong><\/h3>\n\n\n\n

                A shift toward lower margin products can also impact profitability temporarily.<\/p>\n\n\n\n

                However, markets usually focus on whether the company can maintain long term margin sustainability.<\/p>\n\n\n\n

                Why Markets Often Ignore Headline Profit Numbers<\/strong><\/h2>\n\n\n\n

                One of the most important lessons from the Cipla rally is that stock markets are forward looking.<\/p>\n\n\n\n

                Markets care more about future expectations than past numbers.<\/p>\n\n\n\n

                This means investors often focus on:<\/p>\n\n\n\n

                  \n
                • Earnings guidance<\/li>\n\n\n\n
                • Future product launches<\/li>\n\n\n\n
                • Expansion plans<\/li>\n\n\n\n
                • Sector outlook<\/li>\n\n\n\n
                • Management confidence<\/li>\n<\/ul>\n\n\n\n

                  If investors believe future earnings growth remains intact, stocks can rise even after weaker quarterly results.<\/p>\n\n\n\n

                  This explains why companies sometimes rally despite declining profits.<\/p>\n\n\n\n

                  The Bigger Picture: India\u2019s Pharma Sector Remains Attractive<\/strong><\/h2>\n\n\n\n

                  The rally in Cipla Limited also reflects broader optimism around the Indian pharmaceutical sector.<\/p>\n\n\n\n

                  India continues to play an important role in global healthcare due to:<\/p>\n\n\n\n

                    \n
                  • Large scale generic manufacturing<\/li>\n\n\n\n
                  • Cost efficient production<\/li>\n\n\n\n
                  • Strong scientific talent<\/li>\n\n\n\n
                  • Expanding healthcare infrastructure<\/li>\n<\/ul>\n\n\n\n

                    The sector benefits from both domestic demand and export opportunities.<\/p>\n\n\n\n

                    Several long term themes continue supporting Indian pharma:<\/p>\n\n\n\n

                      \n
                    • Rising chronic diseases<\/li>\n\n\n\n
                    • Ageing population<\/li>\n\n\n\n
                    • Increased healthcare spending<\/li>\n\n\n\n
                    • Global demand for affordable medicines<\/li>\n\n\n\n
                    • Government healthcare initiatives<\/li>\n<\/ul>\n\n\n\n

                      Companies with strong balance sheets and diversified portfolios remain attractive to long term investors.<\/p>\n\n\n\n

                      Cipla\u2019s Strength in Respiratory and Chronic Therapies<\/strong><\/h2>\n\n\n\n

                      One of Cipla\u2019s major competitive strengths lies in respiratory therapies.<\/p>\n\n\n\n

                      The company has a strong portfolio in:<\/p>\n\n\n\n

                        \n
                      • Asthma treatments<\/li>\n\n\n\n
                      • Inhalers<\/li>\n\n\n\n
                      • Respiratory medicines<\/li>\n<\/ul>\n\n\n\n

                        Respiratory diseases are increasing globally due to:<\/p>\n\n\n\n

                          \n
                        • Pollution<\/li>\n\n\n\n
                        • Urbanisation<\/li>\n\n\n\n
                        • Lifestyle changes<\/li>\n\n\n\n
                        • Smoking related illnesses<\/li>\n<\/ul>\n\n\n\n

                          This creates a steady demand environment.<\/p>\n\n\n\n

                          Additionally, chronic therapies such as cardiac and diabetes medicines provide recurring demand visibility, which investors generally value highly.<\/p>\n\n\n\n

                          How Investors Should Interpret the Rally<\/strong><\/h2>\n\n\n\n

                          The sharp rise in Cipla shares does not necessarily mean investors ignored the profit decline completely.<\/p>\n\n\n\n

                          Instead, the rally suggests that markets believe:<\/p>\n\n\n\n

                            \n
                          • The decline may be temporary<\/li>\n\n\n\n
                          • Core business fundamentals remain stable<\/li>\n\n\n\n
                          • Future growth opportunities remain strong<\/li>\n\n\n\n
                          • Management execution remains credible<\/li>\n<\/ul>\n\n\n\n

                            This distinction is important for investors.<\/p>\n\n\n\n

                            Markets often differentiate between:<\/p>\n\n\n\n

                              \n
                            • Structural weakness
                              and<\/li>\n\n\n\n
                            • Temporary earnings pressure<\/li>\n<\/ul>\n\n\n\n

                              The positive stock reaction suggests investors currently view Cipla\u2019s challenges as manageable rather than structural.<\/p>\n\n\n\n

                              Opportunities Ahead for Cipla<\/strong><\/h2>\n\n\n\n

                              Growth in Domestic Healthcare Demand<\/strong><\/h3>\n\n\n\n

                              India\u2019s healthcare sector continues expanding rapidly.<\/p>\n\n\n\n

                              Factors driving growth include:<\/p>\n\n\n\n

                                \n
                              • Rising incomes<\/li>\n\n\n\n
                              • Better healthcare access<\/li>\n\n\n\n
                              • Urbanisation<\/li>\n\n\n\n
                              • Increased insurance penetration<\/li>\n<\/ul>\n\n\n\n

                                Pharma companies with strong domestic brands stand to benefit.<\/p>\n\n\n\n

                                Expansion in Global Markets<\/strong><\/h3>\n\n\n\n

                                Cipla continues strengthening its international presence.<\/p>\n\n\n\n

                                Opportunities exist in:<\/p>\n\n\n\n

                                  \n
                                • Generic drug launches<\/li>\n\n\n\n
                                • Respiratory products<\/li>\n\n\n\n
                                • Emerging markets<\/li>\n\n\n\n
                                • Specialty medicines<\/li>\n<\/ul>\n\n\n\n

                                  Increasing Focus on Complex Generics<\/strong><\/h3>\n\n\n\n

                                  Complex generics generally offer better margins than traditional generic medicines.<\/p>\n\n\n\n

                                  Companies capable of developing these products may improve profitability over time.<\/p>\n\n\n\n

                                  Consumer Healthcare Growth<\/strong><\/h3>\n\n\n\n

                                  The consumer healthcare segment also offers diversification opportunities through over the counter products and wellness categories.<\/p>\n\n\n\n

                                  Risks Investors Should Watch Carefully<\/strong><\/h2>\n\n\n\n

                                  Despite the optimism, investors should remain aware of the risks.<\/p>\n\n\n\n

                                  US Pricing Pressure<\/strong><\/h3>\n\n\n\n

                                  The US generic market remains highly competitive.<\/p>\n\n\n\n

                                  Pricing pressure can affect profitability.<\/p>\n\n\n\n

                                  Regulatory Risks<\/strong><\/h3>\n\n\n\n

                                  Pharma companies face strict regulatory oversight globally.<\/p>\n\n\n\n

                                  Any compliance issues can impact operations and investor confidence.<\/p>\n\n\n\n

                                  Currency Volatility<\/strong><\/h3>\n\n\n\n

                                  Export oriented companies are affected by currency fluctuations.<\/p>\n\n\n\n

                                  Margin Pressure<\/strong><\/h3>\n\n\n\n

                                  Higher costs and competition can impact margins over time.<\/p>\n\n\n\n

                                  Patent and Litigation Risks<\/strong><\/h3>\n\n\n\n

                                  Pharmaceutical companies often face legal and intellectual property challenges.<\/p>\n\n\n\n

                                  What Analysts Are Likely Monitoring Next<\/strong><\/h2>\n\n\n\n

                                  After the latest earnings announcement, analysts will likely focus on:<\/p>\n\n\n\n

                                    \n
                                  • Margin trends<\/li>\n\n\n\n
                                  • Domestic growth momentum<\/li>\n\n\n\n
                                  • US business recovery<\/li>\n\n\n\n
                                  • Product approvals<\/li>\n\n\n\n
                                  • Pipeline strength<\/li>\n\n\n\n
                                  • Cost management<\/li>\n\n\n\n
                                  • Export growth<\/li>\n<\/ul>\n\n\n\n

                                    Future quarterly updates will play a major role in determining whether investor optimism continues.<\/p>\n\n\n\n

                                    How Cipla Compares With Other Pharma Stocks<\/strong><\/h2>\n\n\n\n

                                    The Indian pharma sector contains multiple business models.<\/p>\n\n\n\n

                                    Some companies focus heavily on exports, while others rely more on domestic formulations.<\/p>\n\n\n\n

                                    Cipla\u2019s advantage lies in its balanced presence across:<\/p>\n\n\n\n

                                      \n
                                    • Domestic business<\/li>\n\n\n\n
                                    • International markets<\/li>\n\n\n\n
                                    • Respiratory therapies<\/li>\n\n\n\n
                                    • Consumer healthcare<\/li>\n<\/ul>\n\n\n\n

                                      This diversification helps reduce business concentration risk.<\/p>\n\n\n\n

                                      Investors often prefer companies with stable and diversified revenue streams during uncertain market conditions.<\/p>\n\n\n\n

                                      What Retail Investors Can Learn From This Rally<\/strong><\/h2>\n\n\n\n

                                      The Cipla rally offers several important lessons for retail investors.<\/p>\n\n\n\n

                                      Markets Are Forward Looking<\/strong><\/h3>\n\n\n\n

                                      Stocks react to future expectations, not just current quarter numbers.<\/p>\n\n\n\n

                                      Headline Profit Alone Is Not Enough<\/strong><\/h3>\n\n\n\n

                                      Investors should study:<\/p>\n\n\n\n

                                        \n
                                      • Revenue growth<\/li>\n\n\n\n
                                      • Margins<\/li>\n\n\n\n
                                      • Guidance<\/li>\n\n\n\n
                                      • Cash flows<\/li>\n\n\n\n
                                      • Sector outlook<\/li>\n<\/ul>\n\n\n\n

                                        rather than focusing only on net profit.<\/p>\n\n\n\n

                                        Quality Businesses Can Command Premium Valuations<\/strong><\/h3>\n\n\n\n

                                        Companies with strong management and consistent execution often maintain investor confidence even during temporary slowdowns.<\/p>\n\n\n\n

                                        Sector Trends Matter<\/strong><\/h3>\n\n\n\n

                                        Strong sector outlooks can support stock prices despite short term volatility.<\/p>\n\n\n\n

                                        Future Outlook for Cipla<\/strong><\/h2>\n\n\n\n

                                        Looking ahead, Cipla Limited appears positioned to benefit from several structural trends in healthcare and pharmaceuticals.<\/p>\n\n\n\n

                                        Its strengths include:<\/p>\n\n\n\n

                                          \n
                                        • Established domestic brands<\/li>\n\n\n\n
                                        • Strong respiratory portfolio<\/li>\n\n\n\n
                                        • International market presence<\/li>\n\n\n\n
                                        • Diversified business model<\/li>\n\n\n\n
                                        • Operational stability<\/li>\n<\/ul>\n\n\n\n

                                          However, maintaining growth momentum while protecting margins will remain important.<\/p>\n\n\n\n

                                          Investors will closely watch how the company navigates global competition, pricing pressure, and regulatory challenges.<\/p>\n\n\n\n

                                          If execution remains strong, Cipla could continue attracting investor interest over the long term.<\/p>\n\n\n\n

                                          Conclusion<\/strong><\/h2>\n\n\n\n

                                          The sharp rise in Cipla Limited shares despite a decline in Q4 profit highlights how modern markets evaluate businesses beyond headline numbers.<\/p>\n\n\n\n

                                          Investors appeared encouraged by the company\u2019s stable revenue performance, resilient domestic business, operational strength, and positive long term growth outlook. The rally reflects confidence in Cipla\u2019s ability to navigate short term challenges while benefiting from structural growth trends in healthcare and pharmaceuticals.<\/p>\n\n\n\n

                                          At the same time, investors should remain balanced in their approach. The pharmaceutical sector continues facing challenges including pricing pressure, regulatory scrutiny, and margin risks.<\/p>\n\n\n\n

                                          For long term investors, the key will be monitoring execution consistency, growth visibility, and profitability trends in the coming quarters.<\/p>\n\n\n\n

                                          The latest market reaction serves as a reminder that successful investing is not about reacting emotionally to quarterly numbers but understanding the bigger business picture.<\/p>\n\n\n\n

                                          FAQs<\/strong><\/h1>\n\n\n\n

                                          1. Why did Cipla shares rise despite lower Q4 profit?<\/strong><\/h3>\n\n\n\n

                                          Investors focused on strong operational performance, revenue growth, and positive future guidance rather than just the profit decline.<\/p>\n\n\n\n

                                          2. What does Cipla do?<\/strong><\/h3>\n\n\n\n

                                          Cipla Limited manufactures pharmaceutical and healthcare products across multiple therapy areas.<\/p>\n\n\n\n

                                          3. Which segments are important for Cipla?<\/strong><\/h3>\n\n\n\n

                                          Respiratory therapies, chronic medicines, generics, and consumer healthcare are key segments.<\/p>\n\n\n\n

                                          4. Is the profit decline a major concern?<\/strong><\/h3>\n\n\n\n

                                          Markets currently view the decline as manageable rather than a sign of structural weakness.<\/p>\n\n\n\n

                                          5. Why are pharma stocks considered defensive?<\/strong><\/h3>\n\n\n\n

                                          Healthcare demand usually remains stable even during economic slowdowns.<\/p>\n\n\n\n

                                          6. What is driving growth in the Indian pharma sector?<\/strong><\/h3>\n\n\n\n

                                          Rising healthcare spending, chronic diseases, exports, and growing medicine demand.<\/p>\n\n\n\n

                                          7. Does Cipla have international operations?<\/strong><\/h3>\n\n\n\n

                                          Yes, the company operates in multiple international markets including the US and South Africa.<\/p>\n\n\n\n

                                          8. What are complex generics?<\/strong><\/h3>\n\n\n\n

                                          Complex generics are difficult to manufacture medicines that often offer higher margins.<\/p>\n\n\n\n

                                          9. Why is the respiratory business important for Cipla?<\/strong><\/h3>\n\n\n\n

                                          Cipla has a strong portfolio of respiratory medicines and inhalers with stable demand.<\/p>\n\n\n\n

                                          10. What risks does Cipla face?<\/strong><\/h3>\n\n\n\n

                                          Pricing pressure, regulatory risks, margin pressure, and currency fluctuations are major risks.<\/p>\n\n\n\n

                                          11. Why do markets react differently from earnings headlines?<\/strong><\/h3>\n\n\n\n

                                          Markets focus on future growth expectations and business quality rather than just quarterly profits.<\/p>\n\n\n\n

                                          12. Is Cipla a long-term investment stock?<\/strong><\/h3>\n\n\n\n

                                          Many investors view it as a stable long term pharma business due to its diversified operations.<\/p>\n\n\n\n

                                          13. What role does the US market play for Cipla?<\/strong><\/h3>\n\n\n\n

                                          The US generics business remains an important contributor to international growth.<\/p>\n\n\n\n

                                          14. How does inflation impact pharma companies?<\/strong><\/h3>\n\n\n\n

                                          Higher operational and manufacturing costs can affect profitability.<\/p>\n\n\n\n

                                          15. What is the outlook for Indian pharmaceutical companies?<\/strong><\/h3>\n\n\n\n

                                          The long term outlook remains positive due to global and domestic healthcare demand.<\/p>\n\n\n\n

                                          16. Why do pharma companies face regulatory challenges?<\/strong><\/h3>\n\n\n\n

                                          Medicines and manufacturing facilities must meet strict quality and safety standards.<\/p>\n\n\n\n

                                          17. Can pharma stocks remain volatile despite defensive characteristics?<\/strong><\/h3>\n\n\n\n

                                          Yes, quarterly earnings, regulations, and global pricing trends can create volatility.<\/p>\n\n\n\n

                                          18. What are investors watching after Cipla\u2019s results?<\/strong><\/h3>\n\n\n\n

                                          Margins, export growth, product launches, and management guidance are key focus areas.<\/p>\n\n\n\n

                                          19. Does Cipla benefit from rising healthcare awareness?<\/strong><\/h3>\n\n\n\n

                                          Yes, increasing healthcare awareness supports medicine demand across therapy segments.<\/p>\n\n\n\n

                                          20. What is the biggest takeaway from Cipla\u2019s stock rally?<\/strong><\/h3>\n\n\n\n

                                          The rally shows that investor confidence often depends more on future growth potential than short term earnings fluctuations.<\/p>\n\n\n\n

                                          Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n","protected":false},"excerpt":{"rendered":"

                                          Summary Shares of Cipla Limited surged nearly 8% even though the company reported a decline in its Q4 profit. The […]<\/p>\n","protected":false},"author":26,"featured_media":67049,"comment_status":"closed","ping_status":"0","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[948],"tags":[],"class_list":["post-67048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-market-news"],"_links":{"self":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/comments?post=67048"}],"version-history":[{"count":1,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67048\/revisions"}],"predecessor-version":[{"id":67050,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67048\/revisions\/67050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media\/67049"}],"wp:attachment":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media?parent=67048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/categories?post=67048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/tags?post=67048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}